News | July 26, 2024
Laurus Labs posts Q1 FY25 consolidated PAT at Rs. 12.51 Cr
Laurus Labs has reported total income of Rs. 1,197.42 crores during the period ended June 30, 2024
Laurus Labs has reported total income of Rs. 1,197.42 crores during the period ended June 30, 2024
The partnership will significantly advance their sustainability initiatives by meeting around 67% of their power requirements for these plants
The inspection was concluded with two 483 observations
A one-time dose of DURVEQTIX has reduced bleeds post-treatment compared to standard of care with a median annualized bleed rate (ABR) of zero bleeds (range 0 to 9.9)
This strategic move aims to make Cupid's high-quality products more accessible to consumers nationwide
EBITDA grew by 31% YoY with EBITDA margin of 11%, a YoY improvement of over 170bps vs. Q1FY24
The partnership will focus on creating capabilities for quickly and accurately processing vast amounts of clinical data
The drug will be manufactured at the group's formulation manufacturing facility in Ahmedabad SEZ - II, India
Thyrocare Technologies has reported total income of Rs. 160.53 crores during the period ended June 30, 2024
Torrent Pharmaceuticals has reported total income of Rs. 2,883 crores during the period ended June 30, 2024
Subscribe To Our Newsletter & Stay Updated
